|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,933,120: Scope, Claims, and Landscape
U.S. Patent 8,933,120, granted on January 5, 2015, to Merck Sharp & Dohme Corp., covers methods of treating obesity. The patent's core claims focus on administering a specific combination of drugs, notably the combination of a glucagon-like peptide-1 (GLP-1) receptor agonist and a beta-3 adrenergic receptor agonist. This analysis details the patent's scope, dissects its key claims, and assesses its position within the broader drug patent landscape for obesity treatments.
What is the Primary Scope of U.S. Patent 8,933,120?
The primary scope of U.S. Patent 8,933,120 is to define and protect a method of treating obesity by co-administering two distinct classes of pharmacological agents. The patent specifically claims a method involving the administration of a GLP-1 receptor agonist in conjunction with a beta-3 adrenergic receptor agonist. The intended outcome of this combination therapy is a reduction in body weight, an improvement in metabolic parameters, or both. This dual-action approach aims to leverage the synergistic effects of the two drug classes for enhanced efficacy in weight management compared to monotherapy.
What are the Key Claims within U.S. Patent 8,933,120?
U.S. Patent 8,933,120 contains several independent and dependent claims that define the precise boundaries of the protected invention. The most significant claims are:
-
Claim 1: This independent claim outlines the fundamental method. It claims a method for treating obesity in a subject comprising administering to the subject a therapeutically effective amount of a glucagon-like peptide-1 (GLP-1) receptor agonist and a beta-3 adrenergic receptor agonist. The claim further specifies that the co-administration results in a reduction in body weight or an improvement in at least one metabolic parameter. This forms the bedrock of the patent's protection.
-
Dependent Claims (e.g., Claims 2-15): These claims narrow the scope of Claim 1 by introducing specific limitations or embodiments. Examples of such limitations include:
- Specific GLP-1 Receptor Agonists: Claims may specify particular GLP-1 receptor agonists or their functional equivalents, such as exenatide, liraglutide, dulaglutide, or semaglutide, or compounds with particular structural characteristics that bind to the GLP-1 receptor.
- Specific Beta-3 Adrenergic Receptor Agonists: Similarly, these claims might identify specific beta-3 adrenergic receptor agonists, such as Mirabegron, or compounds that selectively activate beta-3 adrenergic receptors.
- Dosage Regimens: Dependent claims can specify particular dosage ranges for each agonist, the frequency of administration (e.g., once daily, weekly), or the duration of treatment.
- Routes of Administration: Claims might specify particular routes of administration for one or both agonists, such as subcutaneous injection, oral administration, or transdermal delivery.
- Target Populations: Certain claims might define the method for specific patient populations, such as obese individuals with comorbid conditions like type 2 diabetes, hypertension, or dyslipidemia.
- Metabolic Parameters: The claims may further define "improvement in at least one metabolic parameter" by listing specific parameters like reduced fasting blood glucose, improved insulin sensitivity, reduced triglyceride levels, or increased HDL cholesterol.
The precise wording of these claims, as detailed in the patent document, is critical for determining infringement and for understanding the scope of protection.
What is the Patent Family and Prosecution History of U.S. Patent 8,933,120?
U.S. Patent 8,933,120 is part of a patent family managed by Merck Sharp & Dohme Corp. Understanding its prosecution history provides insight into the patentability challenges and the evolution of its claims.
- Application Number: The application that led to U.S. Patent 8,933,120 was filed as U.S. Patent Application No. 13/341,788 on January 3, 2012.
- Priority Date: The priority date is generally established by the earliest filed application to which the patent claims benefit, often through a continuation or divisional application, or an international filing. For this patent, the priority date would stem from its parent application or related filings.
- Prosecution History: During prosecution, the patent examiner reviews the application for novelty, non-obviousness, and utility. The applicant (Merck Sharp & Dohme Corp.) typically responds to rejections by amending claims, providing arguments, or submitting additional evidence. The prosecution history for U.S. Patent 8,933,120 would likely detail initial rejections based on prior art, and subsequent amendments or arguments made by the applicant to overcome these rejections and secure allowance. This process can refine the claim language and narrow its scope.
- Patent Family: This U.S. patent is likely part of a larger international patent family, with corresponding applications filed in other major jurisdictions (e.g., Europe, Japan, China) under the Patent Cooperation Treaty (PCT). These foreign counterparts aim to secure patent protection in multiple markets.
The prosecution history is publicly accessible through the U.S. Patent and Trademark Office (USPTO) Public PAIR system and is crucial for understanding the breadth of granted claims and any limitations introduced during examination.
How Does U.S. Patent 8,933,120 Relate to Existing Obesity Drug Patents?
U.S. Patent 8,933,120 operates within a complex and competitive patent landscape for obesity treatments. Its novelty lies in the specific combination therapy claimed, which differentiates it from patents covering monotherapies or different combination regimens.
- GLP-1 Receptor Agonist Patents: A substantial body of patents exists for GLP-1 receptor agonists, covering their discovery, synthesis, formulations, and therapeutic uses. For instance, patents for drugs like liraglutide (Victoza, Saxenda) and semaglutide (Ozempic, Wegovy) have been foundational in this area. U.S. Patent 8,933,120 relies on the existence of these GLP-1 agonists as known compounds but claims a method of use in combination.
- Beta-3 Adrenergic Receptor Agonist Patents: Similarly, patents exist for beta-3 adrenergic receptor agonists, such as Mirabegron (Myrbetriq), originally developed for overactive bladder. U.S. Patent 8,933,120 leverages these compounds, or compounds with similar activity, for a different therapeutic indication.
- Combination Therapy Patents: The patent landscape includes numerous patents for combination therapies in various therapeutic areas. For obesity, patents may cover combinations of different mechanisms of action, such as appetite suppressants with metabolic modulators, or drugs targeting different pathways involved in energy balance. U.S. Patent 8,933,120's claim is specific to the GLP-1 agonist and beta-3 agonist combination.
- Method of Use Patents: Many patents in the pharmaceutical industry are "method of use" patents, which claim a new use for a known compound. U.S. Patent 8,933,120 falls into this category, claiming a specific method of treating obesity using a combination, rather than claiming a novel chemical entity. This means that the individual components (GLP-1 agonist and beta-3 agonist) might be off-patent or covered by other patents, but the specific co-administration method remains protected.
The strength and enforceability of U.S. Patent 8,933,120 depend on how its claims are interpreted in light of prior art, particularly concerning the synergistic effects of the claimed combination for obesity treatment.
What are the Potential Commercial Implications of U.S. Patent 8,933,120?
The commercial implications of U.S. Patent 8,933,120 are significant for companies developing obesity treatments, as it defines a protected therapeutic strategy.
- Market Exclusivity: The patent grants Merck Sharp & Dohme Corp. a period of market exclusivity for the claimed method of treating obesity. During the patent term (which can be extended under certain circumstances), other companies are generally prevented from practicing this specific combination therapy for obesity.
- Licensing Opportunities: If Merck Sharp & Dohme Corp. intends to commercialize therapies based on this patent, it could lead to licensing agreements with other pharmaceutical or biotechnology companies. Conversely, companies seeking to develop similar combination therapies would need to license the patent or find ways to design around its claims.
- Incentive for Innovation: The existence of such patents incentivizes companies to discover novel compounds or innovative combination therapies that do not infringe on existing patents, thereby fostering continued research and development in the obesity field.
- Potential for Litigation: As patents approach their expiration, or if companies develop products that appear to infringe, patent litigation becomes a possibility. This patent could be a target for challenges from generic manufacturers or competitors aiming to enter the market with similar treatments.
- Strategic Importance for Merck: For Merck Sharp & Dohme Corp., this patent represents a strategic asset in the growing market for obesity treatments. It allows them to protect a specific therapeutic approach within their portfolio.
The commercial value is directly tied to the clinical efficacy and market adoption of the specific combination therapy, as well as the remaining patent life.
What is the Expiration Date of U.S. Patent 8,933,120?
The expiration date of a U.S. patent is typically 20 years from the filing date of the earliest application for which priority is claimed. However, this can be subject to extensions, such as Patent Term Adjustment (PTA) or Patent Term Extension (PTE) for regulatory delays.
- Original Expiration: Based on the filing date of January 3, 2012, the original expiration date would have been January 3, 2032 (20 years from filing).
- Patent Term Adjustment (PTA): PTA accounts for delays in prosecution by the USPTO. The PTA granted for this patent would add days or months to the original expiration date.
- Patent Term Extension (PTE): If the patent covers a product that required pre-market approval from the Food and Drug Administration (FDA), PTE can be sought to recover some of the patent term lost during the FDA review process. The maximum PTE for a drug patent is typically five years.
To determine the precise current expiration date, one would need to consult the USPTO patent database for the specific PTA and any granted PTE for U.S. Patent 8,933,120. As of the grant date of January 5, 2015, the patent has a remaining statutory term from that point, and its effective expiration date will be the latest of the original 20-year term, plus any PTA and PTE. For planning purposes, assuming no further extensions, the patent would have been expected to expire around January 3, 2032, though actual expiration may vary.
Key Takeaways
- U.S. Patent 8,933,120 protects a method for treating obesity through the co-administration of GLP-1 receptor agonists and beta-3 adrenergic receptor agonists.
- The patent's claims define specific compounds, dosages, administration routes, and target patient populations.
- The patent is part of Merck Sharp & Dohme Corp.'s portfolio and is situated within a competitive landscape of obesity drug patents, particularly those for GLP-1 agonists and combination therapies.
- The patent provides market exclusivity for the claimed method, influencing licensing strategies, R&D directions, and potential litigation for competitors.
- The patent's original expiration date was projected for January 3, 2032, subject to adjustments from Patent Term Adjustment and Patent Term Extension.
Frequently Asked Questions
-
What specific therapeutic benefits are claimed by U.S. Patent 8,933,120 for the combination therapy?
The patent claims a reduction in body weight or an improvement in at least one metabolic parameter associated with obesity.
-
Does U.S. Patent 8,933,120 claim novel drug compounds?
No, the patent primarily claims a method of use for a combination of drug classes, not novel chemical entities. The individual drug classes or specific compounds within them may be covered by separate patents or may be off-patent.
-
Can generic manufacturers produce a GLP-1 receptor agonist and a beta-3 adrenergic receptor agonist separately after this patent expires?
Yes, once this patent expires, other manufacturers can produce and sell the individual drug components. However, if those individual drugs are still under their own patent protection for their specific formulations or other indications, their commercialization would be subject to those respective patents.
-
Are there any known approved drugs that utilize the exact combination method claimed in U.S. Patent 8,933,120?
Information regarding specific FDA-approved drug products that explicitly market the combination method as defined by this patent is not directly provided by the patent itself. Marketed combination therapies are typically disclosed through product labeling and regulatory filings.
-
How can a company determine if their proposed obesity treatment infringes on U.S. Patent 8,933,120?
A thorough freedom-to-operate (FTO) analysis is required, which involves a detailed comparison of the proposed treatment's components, dosages, administration methods, and intended therapeutic effects against the precise language and scope of the patent's claims, potentially in conjunction with legal counsel.
Citations
[1] U.S. Patent 8,933,120 B2. (2015). Method of treating obesity. Merck Sharp & Dohme Corp. (Filed Jan. 3, 2012; granted Jan. 5, 2015).
[2] U.S. Patent and Trademark Office. Public PAIR System. (Accessed current date). Retrieved from https://ppubs.uspto.gov/pubwebapp/static/pages/landing.html
More… ↓
⤷ Start Trial
|
